+34 9340006100 -ext. 437807-info@nanbiosis.com
 |
This Unit is located in the Hospital de la Santa Creu i Sant Pau, in Barcelona, and is coordinated by Dr. Ramón Mangues, PI of the Oncogenesis and Antitumor Drug Group. The main objective of the Nanotoxicology Unit is to assess the toxicity of new drugs, nanoparticles or nanotechnology-based biomaterials in in vitro and in vivo systems, with the goal of optimizing lead compounds and identifying those with the highest probability of success in the preclinical programme due to their greater safety and tolerability or reduced toxicity. The Unit has rooms equipped for cell culture, for cryopreservation of samples and cell lines, and for sample preparation and analysis and animal facilities for in vivo experimentation.
Equipment: The Unit has access to flow cytometers, sorters, confocal microscope and other equipment of the Platforms available at the Hospital Research Institute as well as housing facilities for small rodents (rat and mouse).
FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
| Title | Fundin: Organism | Call: Funding source | Role | ||
|---|---|---|---|---|---|
| ICTS-2017-10-CIBER-2 |  | Acquisition and istallation of infrastrucuture to complemntUnis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivoExperiment | Ministerio de Economía, Industria y Competitividad (MINECO) | Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt) | Coordinator |
| SAF2017-90810-REDI | | Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II | Agencia Estatal de Investigación (AEI) | Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 | Coordinator |
| Ref | Title | Funding Organism | Unit Role |
|---|---|---|---|
| PI15/00378 | Intelligent nanoconjugates for targeted therapy of metastatic colorectal cancer (CRC) | Instituto de Salud Carlos III | Working package |
| PIE15/00028 | Targeted nanocongugates for the selective elimination of stem cells in disseminated cancer | Instituto de Salud Carlos III | Working package |
| PI15/00272 | Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. | Instituto de Salud Carlos III | Participant |
| CP15/00163 | Maria Virtudes Céspedes Navarro Contracts Miguel Servet Type I | Instituto de Salud Carlos III | Working package |
| CD14/00055 | Contract SARA BORRELL | Instituto de Salud Carlos III | Working package |
| Marato 416/C/2030TV32013-132031 | Genotoxic nanoparticles targeting colorectal cancer stem cells | Marato TV3 | Participant |
28 Sep
September 27th 2022 – Nanoligent SL, a Spanish biotech company specialized in the development of cancer treatments based on unique protein conjugates, today announces the completion of a Seed financing round of total € 2.8 M. The final closing of the Seed round consists of € 1 M investment by i&i Biotech Fund I (i&i Bio), an early-stage Life Science fund with teams in Luxemburg and Prague which is backed by the European Investment Fund. i&i Bio joined previous Nanoligent investors, Italian Angels for Growth, the largest network of business angels in Italy, and AVANTECA Partners, a Swiss privately held[...]
02 May
During the last 27-29 April, the 3rd International Conference on Nanomaterials Applied to Life Sciences 2022 (NALS 2022) has taken place in the Excellence Campus of Universidad de Cantabria in Santander (Spain), organized by the University of Cantabria and Institute Valdecilla-IDIVAL. NALS 2022 has been a multidisciplinary conference series sharing new results and ideas in the fields of biosensors, lab on a chip, drug delivery nanopharmacy. nanobiotechnology, intelligent nanomaterials, magnetic materials, nanotoxicity, antimicrobials, novel applications of 3d bioprinting and nanoimaging. NANBIOSIS has been represented at this edition by members of several of its units, among them we must highlight the set of four ora[...]
03 Feb
Barcelona, Spain – Milan, Italy, February 3rd, 2022 – Nanoligent SL, a biotech company specialized in the development of nanotechnology-based cancer treatments, today announces the completion of the first closing of a Seed financing round of €1M. The round has been led by members of Italian Angels for Growth, the largest network of business angels in Italy, through the investment vehicle Nanolinvest, and AVANTECA Partners, a Swiss privately held asset management firm, both specialized in supporting innovative early-stage life-science companies primarily in Europe. An equity campaign, is still ongoing on Doorway, an online investment platform, thus promising to provide additional funding[...]
29 Oct
Dr. Ramon Mangues, head of the Oncogenesis and Antitumor Group and Scientific Director of NANBIOSIS U18 Nanotoxicology Unit of CIBER-BBN at the Sant Pau Research Institute, has been recently elected as a new member of the Royal Academy of Pharmacy of Catalonia. The celebration will take place on November 8 at 7 pm, at the headquarters of the RAFC, (Royal Academy of Pharmacy of Catalonia) which was the headquarters of the old Hospital de la Santa Cruz since the 15th century, located at Calle del Hospital, 56, in Barcelona. During the event, Dr. Mangues will read his admission speech “Selectiv[...]
16 Mar
The Nanotoxicology Unit of CIBER-BBN ICTS NANBIOSIS (u18-nanotoxicology-unit), led by Ramon Mangues at the Research Institute of the Hospital de Sant Pau and the NABIOSIS (nanbiosis.es)Protein Production Platform (u1-protein-production-platform-ppp) led by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, have participated in the development of a novel drug delivery system able to achieve sustained release of proteins with intrinsic antitumor activity. This delivery system consists on inclusion bacterial bodies formed by recombinant fusion proteins that precipitate while being expressed in bacteria, acquiring an amyloid structure, but remaining functional. Thus,[...]
25 Feb
Researchers of the Nanotoxicology Unit of the the CIBER-BBN ICTS NANBIOSIS (u18-nanotoxicology-unit), leaded by Ramon Mangues and Isolda Casanova at the Research Institute of the Hospital de Sant Pau and of the NANBIOSIS (nanbiosis.es) Protein Platform (u1-protein-production-platform-ppp) leaded by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, have developed a novel protein-Auristatin nanoconjugate that specifically targets CXCR4-overexpressing acute myeloid leukemia (AML) cells. It selectively accumulates in target cancer cells expressing this receptor and deliver the toxin Auristatin within their cytosol. There, Auristatin potently blocks microtubule polymerization, provoking mitotic catastrophe,[...]
21 Feb
Researchers at the Nanotoxicology Unit of CIBER-BBN ICTS NANBIOSIS (u18-nanotoxicology-unit), led by Ramon Mangues and Isolda Casanova of the Research Institute at the Hospital de Sant Pau and the Researchers of the NANBIOSIS (nanbiosis.es) Protein Production Platform (u1-protein-production-platform-ppp) led by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, have participated in the development of a novel protein nanoparticle that incorporates the Exotoxin of the bacteria Pseudomonas aeruginosa, capable of targeting lymphoma cells that overexpress the CXCR4 receptor. They internalize selectively in target cancer cells through CXCR4 receptor-mediated endocytosis du[...]
15 Feb
Researchers of the Nanotoxicology Unit (u18-nanotoxicology-unit) led by Ramon Mangues and Isolda Casanova at the Research Institute of the Hospital de Sant Pau and the Protein Production Platform (u1-protein-production-platform-ppp), led by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, both belonging to the ICTS NANBIOSIS (nanbiosis.es) of the CIBER-BBN, have participated in the production of a novel Nanotoxin capable of selectively killing cancer cells which became resistant to chemotherapy. Development of cancer resistance frequently associates with the overexpression of the CXCR4 receptor. It is known that chemotherapy kills cancer[...]
